Home / Health / New At-Home Test Detects Colon Cancer Early
New At-Home Test Detects Colon Cancer Early
23 Jun
Summary
- ColoSense uses RNA to detect cancer and precancerous changes.
- Test offers easier sample collection than older methods.
- Available nationwide for eligible Medicare beneficiaries.
Labcorp is now offering ColoSense, a new FDA-approved at-home screening test for colorectal cancer. This innovative test utilizes ribonucleic acid (RNA) technology to detect biomarkers associated with both colorectal cancer and advanced adenomas, which are precancerous lesions. Developed by Geneoscopy, ColoSense has demonstrated high sensitivity, with clinical data showing 93% for detecting colorectal cancer in average-risk individuals and 100% for stage I cancer.
The test is designed to simplify the screening process for patients aged 45 to 85 considered at average risk. Previous at-home tests have faced challenges with user comfort and sample preparation. ColoSense aims to overcome these by providing an easy-to-use kit that minimizes direct handling and eliminates complex sample mixing. This advancement is particularly beneficial for eligible Medicare and Medicare Advantage beneficiaries, with broader commercial coverage also available.
ColoSense has received endorsements from major cancer organizations, including the American Cancer Society and the National Comprehensive Cancer Network, solidifying its role as a recommended screening tool. It is important to note that while ColoSense is a powerful screening option, it does not replace the need for diagnostic colonoscopies.
